Hysbysiad dyfarnu contract

Canlyniadau'r weithdrefn gaffael

Adran I: Endid contractio

I.1) Enw a chyfeiriad

I.2) Caffael ar y cyd

Caiff y contract ei ddyfarnu gan gorff prynu canolog

I.4) Y math o awdurdod contractio

Corff a lywodraethir gan gyfraith gyhoeddus

I.5) Prif weithgaredd

Iechyd

Adran II: Gwrthrych

II.1) Cwmpas y caffaeliad

II.2) Disgrifiad

Section IV: Gweithdrefn

IV.1) Disgrifiad

Section V: Dyfarnu contract

Rhif Contract: CAV-DAP2 (26-27) 18

Dyfernir contract/lot: Ydy

V.2 Dyfarnu contract

V.2.1) Y dyddiad y daeth y contract i ben

20/05/2026

V.2.2) Gwybodaeth am dendrau

Nifer y tendrau a ddaeth i law: 1

Nifer y tendrau a ddaeth i law gan BBaChau: 1

Nifer y tendrau a dderbyniwyd gan dendrwyr o Aelod-wladwriaethau yr UE: 0

Nifer y tendrau a dderbyniwyd gan dendrwyr o Aelod-wladwriaethau nad ydynt yn aelodau o'r UE: 0

Nifer y tendrau a ddaeth i law drwy ddulliau electronig: 0

Dyfarnwyd y contract i gr?p o weithredwyr economaidd: Na

V.2.3) Enw a chyfeiriad y contractwr

V.2.4) Gwybodaeth am werth y contract/lot (heb gynnwys VAT)

Amcangyfrif cychwynnol o gyfanswm gwerth y contract/lot: 274 200.00 GBP

Cyfanswm gwerth y contract/lot: 274 200.00 GBP

V.2.5) Gwybodaeth am is-gontractio

Section VI: Gwybodaeth ategol

VI.3) Gwybodaeth ychwanegol

This is a Provider Selection Regime Wales (PSR Wales) intention to award notice. The awarding of this contract is subject to the Health Services (Provider Selection Regime) (Wales) Regulations 2025. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015/Procurement Act 2023 do not apply to this award. The publication of this notice marks the start of the standstill period. Representations by providers must be made to decision makers by 02/06/2026. This contract has not yet formally been awarded; this notice serves as an intention to award under the PSR Wales.

Providers should send their written representation during the standstill period to Sam.Davies8@wales.nhs.uk

The Cardiff and Vale University Health Board intends to utilise Direct Award Process 2 under the Provider Selection Regime (Wales) to award a contract for the provision of Mobile Lithotripsy Services to the incumbent provider.

- No providers were excluded from this Procurement

- There were no declared conflicts of individuals making the decision

- There is no information withheld under regulation 23 (1)

1. Applicability of Direct Award Process 2

Direct Award Process 2 is considered appropriate where:

· The existing provider is delivering services to an acceptable standard, and

· Changing provider would likely result in disruption, reduced quality, or disproportionate costs/risk, and

· The service is of a nature where continuity and integration are critical to patient outcomes.

The current service provided by the incumbent provider meets these criteria.

2. Performance of Current Provider

The incumbent provider has:

· Consistently delivered safe, high-quality lithotripsy services in line with clinical requirements

· Demonstrated strong clinical outcomes and patient satisfaction

· Maintained compliance with all contractual KPIs and governance standards

· Established effective clinical integration with Urology, Radiology, and surgical teams.

There are no significant performance concerns that would justify market testing at this time.

3. Continuity of Care and Clinical Integration

Mobile Lithotripsy is a highly specialised, pathway critical service, requiring:

· Integration with pre and post procedure diagnostic pathways

· Coordination with theatre scheduling, imaging, and urology clinics

· Established clinical protocols and multidisciplinary working

A change in provider would introduce:

· Risk of service disruption and delays in treatment

· Loss of embedded processes and clinical familiarity

· Potential impact on waiting time performance and patient outcomes

Maintaining the current provider supports continuity of care and pathway stability.

4. Technical and Operational Considerations

The incumbent provider:

· Supplies specialist mobile equipment aligned with site infrastructure

· Provides experienced clinical and technical staff familiar with local systems

· Has established operational logistics for mobile unit deployment

Transitioning to a new provider would require:

· Equipment validation and compatibility checks

· Staff onboarding and training

· Reconfiguration of operational pathways

This would result in avoidable cost, delay, and operational risk.

5. Value for Money

The current arrangement:

· Provides demonstratable value for money

· Avoids mobilisation costs associated with a new provider

· Minimises inefficiencies during transaction period

A competitive process is unlikely to delivery significantly improved value when factoring in transition risks and costs.

6. Patient Impact

Maintaining the current provider supports:

· Timely access to treatment, reducing waiting list pressures

· Continuity in patient experience and clinical outcomes

· Minimisation of clinical risk associated with change

(WA Ref:164966)

VI.4) Gweithdrefnau adolygu

VI.5) Dyddiad anfon yr hysbysiad hwn

20/05/2026